BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huff J, Andersen R. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older. Ann Pharmacother 2020;54:262-76. [PMID: 31537106 DOI: 10.1177/1060028019877128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Voight EA, Greszler SN, Hartung J, Ji J, Klix RC, Randolph JT, Shelat BH, Waters JE, DeGoey DA. Desymmetrization of pibrentasvir for efficient prodrug synthesis. Chem Sci 2021;12:10076-82. [PMID: 34349971 DOI: 10.1039/d1sc02396a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2020;63:11034-44. [PMID: 32881503 DOI: 10.1021/acs.jmedchem.0c00956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]